An increase in cancer stem cell population after primary systemic therapy is a poor prognostic factor in breast cancer

被引：0
|
作者：
H E Lee
J H Kim
Y J Kim
S Y Choi
S-W Kim
E Kang
I Y Chung
I A Kim
E J Kim
Y Choi
H S Ryu
S Y Park
机构：
[1] Seoul National University Hospital,Department of Pathology
[2] Seoul National University College of Medicine,Department of Internal Medicine
[3] Seoul National University College of Medicine,Department of Surgery
[4] Breast Care Center,Department of Radiation Oncology
[5] Seoul National University Bundang Hospital,Department of Pathology
[6] 300 Gumi-dong,Department of Pathology
[7] Bundang-gu,undefined
[8] Seongnam-si,undefined
[9] Gyeonggi 463-707,undefined
[10] Korea,undefined
[11] Seoul National University College of Medicine,undefined
[12] Seoul National University Bundang Hospital,undefined
[13] Seoul National University College of Medicine,undefined
来源：
British Journal of Cancer | 2011年 / 104卷
关键词：
breast cancer; cancer stem cells; primary systemic therapy; chemoresistance;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1730 / 1738
页数：8
相关论文
共 50 条
  • [31] Interleukin-17-producing cell infiltration in the breast cancer tumour microenvironment is a poor prognostic factor
    Chen, Wen-Chung
    Lai, Yu-Hsuan
    Chen, Hung-Yu
    Guo, How-Ran
    Su, Ih-Jen
    Chen, Helen H. W.
    HISTOPATHOLOGY, 2013, 63 (02) : 225 - 233
  • [32] Unargued issues on the pathological assessment of response in primary systemic therapy for breast cancer
    Kuroi, K
    Toi, M
    Tsuda, H
    Kurosumi, M
    Akiyama, F
    BIOMEDICINE & PHARMACOTHERAPY, 2005, 59 : S387 - S392
  • [33] Adjuvant anthracycline therapy as a prognostic factor in metastatic breast cancer
    Emilio Alba
    Nuria Ribelles
    Isabel Sevilla
    Antonio Rueda
    Lorenzo Alonso
    Antonia Marquez
    Inmaculada Ruiz
    José Miramón
    Breast Cancer Research and Treatment, 2001, 66 : 33 - 39
  • [34] Adjuvant anthracycline therapy as a prognostic factor in metastatic breast cancer
    Alba, E
    Ribelles, N
    Sevilla, I
    Rueda, A
    Alonso, L
    Marquez, A
    Ruiz, I
    Miramón, J
    BREAST CANCER RESEARCH AND TREATMENT, 2001, 66 (01) : 33 - 39
  • [35] Systemic Immune-Inflammation Index Is a Prognostic Factor for Breast Cancer Patients After Curative Resection
    Li, Wen
    Ma, Guangzhi
    Deng, Yunfu
    Chen, Wenjie
    Liu, Zhenkun
    Chen, Fang
    Wu, Qiang
    FRONTIERS IN ONCOLOGY, 2021, 11
  • [36] SCUBE3 serves as an independent poor prognostic factor in breast cancer
    Qin Huo
    Xi He
    Zhenwei Li
    Fan Yang
    Shengnan He
    Ling Shao
    Ye Hu
    Siqi Chen
    Ni Xie
    Cancer Cell International, 21
  • [37] EMI2 expression as a poor prognostic factor in patients with breast cancer
    Vadhan, Anupama
    Wang, Yen-Yun
    Yuan, Shyng-Shiou F.
    Lee, Yi-Chen
    Hu, Stephen Chu-Sung
    Huang, Jyun-Yuan
    Ishikawa, Takashi
    Hou, Ming-Feng
    KAOHSIUNG JOURNAL OF MEDICAL SCIENCES, 2020, 36 (08) : 640 - 648
  • [38] SCUBE3 serves as an independent poor prognostic factor in breast cancer
    Huo, Qin
    He, Xi
    Li, Zhenwei
    Yang, Fan
    He, Shengnan
    Shao, Ling
    Hu, Ye
    Chen, Siqi
    Xie, Ni
    CANCER CELL INTERNATIONAL, 2021, 21 (01)
  • [39] BREAST CANCER STEM CELLS - DIAGNOSTIC AND PROGNOSTIC SIGNIFICANCE
    Petrova, Zdravka
    Spasov, Rossen
    Alexandrova, Radostina
    COMPTES RENDUS DE L ACADEMIE BULGARE DES SCIENCES, 2024, 77 (01): : 40 - 47
  • [40] Primary systemic therapy does not eradicate disseminated tumor cells in breast cancer patients
    Becker, Sven
    Solomayer, Erich
    Becker-Pergola, Graziella
    Wallwiener, Diethelm
    Fehm, Tanja
    BREAST CANCER RESEARCH AND TREATMENT, 2007, 106 (02) : 239 - 243
12345